Literature DB >> 25446551

Osteopontin binding to the alpha 4 integrin requires highest affinity integrin conformation, but is independent of post-translational modifications of osteopontin.

Tommy Hui1, Esben S Sørensen2, Susan R Rittling3.   

Abstract

Osteopontin (OPN) is a ligand for the α4ß1 integrin, but the physiological importance of this binding is not well understood. Here, we have assessed the effect of post-translational modifications on OPN binding to the α4 integrin on cultured human leukocyte cell lines and compared OPN interaction with α4 integrin to that of VCAM and fibronectin. Jurkat cells, whose α4 integrins are inherently activated, adhered to different preparations of OPN in the presence of Mn(2+): the EC50 of adhesion was not affected by phosphorylation or glycosylation status. Thrombin cleavage of OPN at the C-terminus of the α4 integrin-binding site also did not affect binding affinity. THP-1 cells express a low-affinity conformation of the integrin and adhered to OPN only in the presence of Mn(2+) plus PMA or an activating antibody. This was in contrast to VCAM and fibronectin: THP-1 cells adhered to these ligands without integrin activation. Studies with ligand-induced binding site antibodies demonstrated that the SVVYGLR peptide of OPN bound to the α4 integrin with a similar affinity as the LDV peptide of fibronectin, suggesting that a high off-rate is responsible for the reduced binding of OPN to the low-affinity forms of this integrin. Together, the results suggest OPN has very low affinity for the α4 integrin on human leukocytes under physiological conditions.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Adhesion; Integrin Alpha4; Osteopontin; Phosphorylation; VCAM; VLA-4

Mesh:

Substances:

Year:  2014        PMID: 25446551      PMCID: PMC4912046          DOI: 10.1016/j.matbio.2014.11.005

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  29 in total

1.  Real time analysis of the affinity regulation of alpha 4-integrin. The physiologically activated receptor is intermediate in affinity between resting and Mn(2+) or antibody activation.

Authors:  A Chigaev; A M Blenc; J V Braaten; N Kumaraswamy; C L Kepley; R P Andrews; J M Oliver; B S Edwards; E R Prossnitz; R S Larson; L A Sklar
Journal:  J Biol Chem       Date:  2001-10-18       Impact factor: 5.157

2.  Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1.

Authors:  F Sanz-Rodríguez; A Hidalgo; J Teixidó
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

3.  Tumor-derived osteopontin is soluble, not matrix associated.

Authors:  Susan R Rittling; Yanping Chen; Fei Feng; Yiming Wu
Journal:  J Biol Chem       Date:  2001-12-12       Impact factor: 5.157

4.  Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.

Authors:  Brian Christensen; Mette S Nielsen; Kim F Haselmann; Torben E Petersen; Esben S Sørensen
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

5.  A regulated interaction between alpha5beta1 integrin and osteopontin.

Authors:  S T Barry; S B Ludbrook; E Murrison; C M Horgan
Journal:  Biochem Biophys Res Commun       Date:  2000-01-27       Impact factor: 3.575

6.  Human Plasma Fibronectin Mediates Adhesion of U937 Cells by RGD and CS1.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

7.  Ca2+ suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin alpha v beta 3.

Authors:  D D Hu; J R Hoyer; J W Smith
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

8.  Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation.

Authors:  Alexandre Chigaev; Anna Waller; Or Amit; Liliana Halip; Cristian G Bologa; Larry A Sklar
Journal:  J Biol Chem       Date:  2009-02-27       Impact factor: 5.157

9.  Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion.

Authors:  Alexandre Chigaev; Larry A Sklar
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

10.  Osteopontin is a ligand for the alpha4beta1 integrin.

Authors:  K J Bayless; G A Meininger; J M Scholtz; G E Davis
Journal:  J Cell Sci       Date:  1998-05       Impact factor: 5.285

View more
  12 in total

1.  Prostate cancer sheds the αvβ3 integrin in vivo through exosomes.

Authors:  Shiv Ram Krishn; Amrita Singh; Nicholas Bowler; Alexander N Duffy; Andrea Friedman; Carmine Fedele; Senem Kurtoglu; Sushil K Tripathi; Kerith Wang; Adam Hawkins; Aejaz Sayeed; Chirayu P Goswami; Madhukar L Thakur; Renato V Iozzo; Stephen C Peiper; William K Kelly; Lucia R Languino
Journal:  Matrix Biol       Date:  2018-08-08       Impact factor: 11.583

2.  Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer.

Authors:  Huimin Lu; Nicholas Bowler; Larry A Harshyne; D Craig Hooper; Shiv Ram Krishn; Senem Kurtoglu; Carmine Fedele; Qin Liu; Hsin-Yao Tang; Andrew V Kossenkov; William K Kelly; Kerith Wang; Rhonda B Kean; Paul H Weinreb; Lei Yu; Anindita Dutta; Paolo Fortina; Adam Ertel; Maria Stanczak; Flemming Forsberg; Dmitry I Gabrilovich; David W Speicher; Dario C Altieri; Lucia R Languino
Journal:  Matrix Biol       Date:  2018-03-09       Impact factor: 11.583

3.  Modulation of infection-mediated migration of neutrophils and CXCR2 trafficking by osteopontin.

Authors:  Rani Singh; Tommy Hui; Aritsune Matsui; Ziyad Allahem; Christopher D Johnston; Montserrat Ruiz-Torruella; Susan R Rittling
Journal:  Immunology       Date:  2016-10-07       Impact factor: 7.397

Review 4.  Osteopontin in Immune-mediated Diseases.

Authors:  S R Rittling; R Singh
Journal:  J Dent Res       Date:  2015-09-04       Impact factor: 6.116

Review 5.  Osteopontin -- a promising biomarker for cancer therapy.

Authors:  Ran Wei; Janet Pik Ching Wong; Hang Fai Kwok
Journal:  J Cancer       Date:  2017-07-15       Impact factor: 4.207

6.  Integrin Activation Contributes to Lower Cisplatin Sensitivity in MV3 Melanoma Cells by Inducing the Wnt Signalling Pathway.

Authors:  Maria B R Piva; Bastian Jakubzig; Gerd Bendas
Journal:  Cancers (Basel)       Date:  2017-09-16       Impact factor: 6.639

7.  Antibody-mediated targeting of cleavage-specific OPN-T cell interactions.

Authors:  Bettina Wanko; Matteo Tardelli; Alexander Jürets; Angelika Neuhofer; Gerhard Prager; John Morser; Lawrence L Leung; Günther Staffler; Maximilian Zeyda; Thomas M Stulnig
Journal:  PLoS One       Date:  2019-04-05       Impact factor: 3.240

8.  Structural Constraint of Osteopontin Facilitates Efficient Binding to CD44.

Authors:  Gulimirerouzi Fnu; Palak Agrawal; Gopal C Kundu; Georg F Weber
Journal:  Biomolecules       Date:  2021-05-30

9.  Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin Cleavage.

Authors:  Alexander Jürets; Marie Le Bras; Günther Staffler; Gesine Stein; Lukas Leitner; Angelika Neuhofer; Matteo Tardelli; Edvin Turkof; Maximilian Zeyda; Thomas M Stulnig
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

10.  Synthesis of a Cleaved Form of Osteopontin by THP-1 Cells and Its Alteration by Phorbol 12-Myristate 13-Acetate and BCG Infection.

Authors:  Gaowa Bai; Hirotoshi Motoda; Ryo Ozuru; Haorile Chagan-Yasutan; Toshio Hattori; Takashi Matsuba
Journal:  Int J Mol Sci       Date:  2018-01-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.